Published in J Antimicrob Chemother on November 01, 1989
Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues. Antimicrob Agents Chemother (1994) 0.80
Bone penetration of amoxicillin and clavulanic acid evaluated by population pharmacokinetics and Monte Carlo simulation. Antimicrob Agents Chemother (2009) 0.79
Concentrations of amoxicillin and clindamycin in teeth following a single dose of oral medication. Clin Oral Investig (2013) 0.76
Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol (1985) 5.67
Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother (1985) 4.07
Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother (1987) 3.09
[Azlocillin and mezlocillin: two new semisynthetic acylureido-penicillins (author's transl)]. Infection (1977) 2.54
Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in Xiphophorus. Nature (1989) 2.44
Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother (1979) 2.23
FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell (1996) 2.15
A program for non-linear regression analysis to be used on desk-top computers. Comput Programs Biomed (1980) 2.03
Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol (1986) 2.00
67 Ga for tumor scanning. J Nucl Med (1972) 1.97
Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol (1985) 1.86
Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother (2000) 1.80
Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling. J Biol Chem (1999) 1.70
Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J (1995) 1.70
[Diffusion of cefamandole into the prostatic tissue (author's transl)]. Med Klin (1979) 1.70
[First experiences with the broad spectrum antimycotic BAY b 5097]. Med Klin (1969) 1.64
Comparative pharmacokinetics of cefoperazone and cefotaxime. Clin Ther (1980) 1.46
Pharmacodynamics of fluoroquinolones. Clin Infect Dis (1998) 1.42
Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination. Antimicrob Agents Chemother (1982) 1.42
Fears rise over BSE infection in UK abattoirs. Nature (2001) 1.41
Azithromycin--review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother (1996) 1.40
Museum suffers spiritual cramps over Mendel's work. Nature (2001) 1.39
Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother (1983) 1.39
Large Hadron Collider in crisis as magnet costs spiral upwards. Nature (2001) 1.39
Quinolone antibacterials. An update of their pharmacology and therapeutic use. Drugs (1994) 1.39
Researchers strike back in animal-rights row. Nature (2001) 1.38
Comparative pharmacokinetics of apalcillin and piperacillin. Antimicrob Agents Chemother (1984) 1.28
[Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin]. Antimicrob Agents Chemother (1975) 1.26
State of the rigid-layer in celll walls of some gram-negative Bacteria. Arch Mikrobiol (1972) 1.24
Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother (1999) 1.24
Comparative pharmacokinetics of new quinolones. Drugs (1987) 1.22
Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med (2000) 1.19
Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother (1996) 1.19
Enhanced in vitro phagocytosis of Listeria monocytogenes by human monocytes in the presence of ampicillin, tetracycline, and chloramphenicol. Infect Immun (1974) 1.14
Cross-linking of surface immunoglobulin activates src-related tyrosine kinases in WEHI 231 cells. Biochem Biophys Res Commun (1992) 1.12
Arabidopsis thaliana genome. Now for the hard ones. Nature (2000) 1.11
Bay B 5097, a new orally applicable antifungal substance with broadspectrum activity. Preliminary clinical and laboratory experiences in children. Acta Paediatr Scand (1971) 1.10
[In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections]. Infection (1986) 1.09
Ctk: a protein-tyrosine kinase related to Csk that defines an enzyme family. Proc Natl Acad Sci U S A (1994) 1.08
Multiple dose pharmacokinetics and therapeutic results with ceftazidime. J Antimicrob Chemother (1983) 1.07
Genetics group targets disease markers in the human sequence. Nature (2001) 1.06
Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer (1994) 1.04
Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother (1983) 1.03
Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother (1992) 1.02
Distinct adapter proteins mediate acid versus neutral sphingomyelinase activation through the p55 receptor for tumor necrosis factor. J Leukoc Biol (1998) 1.02
Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother (1989) 1.00
Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother (1992) 1.00
When the going gets tough... Nature (2001) 1.00
Tumor necrosis factor (TNF)-alpha activates c-raf-1 kinase via the p55 TNF receptor engaging neutral sphingomyelinase. EMBO J (1995) 1.00
Effect of dihydrostreptomycin on phagocytosis of mouse-peritoneal macrophages in vitro. Infect Immun (1972) 1.00
Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother (1983) 0.99
Measurement of lung density by computed tomography. J Comput Assist Tomogr (1978) 0.99
Cefotaxime in bronchopulmonary infections--a clinical and pharmacological study. J Antimicrob Chemother (1980) 0.98
Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother (1988) 0.97
Function of the p55 tumor necrosis factor receptor "death domain" mediated by phosphatidylcholine-specific phospholipase C. J Exp Med (1996) 0.96
[Blood levels of cephalothin in normal and impaired renal function]. Int Z Klin Pharmakol Ther Toxikol (1972) 0.96
Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf (1995) 0.95
On the peptidoglycan of the cell walls of Pseudomonas aeruginosa. Eur J Biochem (1972) 0.95
Simultaneous cytofluorometric measurement of phagocytosis, burst production and killing of human phagocytes using Candida albicans and Staphylococcus aureus as target organisms. Clin Microbiol Infect (2000) 0.94
Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J Infect Dis (1976) 0.94
Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother (1994) 0.92
Concentrations of ofloxacin in human bone and in cartilage. J Antimicrob Chemother (1990) 0.92
Adenovirus infection in cystic fibrosis patients: implications for the use of adenoviral vectors for gene transfer. Infection (1996) 0.90
Pharmacokinetics of Cefmenoxime in normal and impaired renal function. Arzneimittelforschung (1983) 0.90
In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. Drugs (1987) 0.89
Characterization of regional left ventricular contraction by curvature difference analysis. Basic Res Cardiol (1989) 0.89
[Studies on the pharmacokinetics of amoxicillin after intravenous, intramuscular and oral administration (author's transl)]. Arzneimittelforschung (1981) 0.89
[Purification and properties of 3-hydroxyanthranilate oxygenase from Saccharomyces cerevisae]. Hoppe Seylers Z Physiol Chem (1968) 0.89
Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother (1997) 0.88
[Comparative pharmacokinetics of oral cephalosporins: cephalexin, cefaclor and cefadroxil (author's transl)]. Arzneimittelforschung (1980) 0.88
Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. Antimicrob Agents Chemother (1996) 0.88
Gene therapy may be up to speed for cheats at 2008 Olympics. Nature (2001) 0.88
The effects of recurrent inhibition on the cross-correlated firing patterns of motoneurones (and their relation to signal transmission in the spinal cord-muscle channel). Biol Cybern (1978) 0.87
Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers. Drugs (1988) 0.87
Concentrations of ticarcillin and clavulanic acid in human bone after prophylactic administration of 5.2 g of timentin. Antimicrob Agents Chemother (1987) 0.87
[On the regulation of nicotinic acid biosynthesis in Saccharomyces cerevisiae]. Hoppe Seylers Z Physiol Chem (1968) 0.87
Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother (1990) 0.87
Activation of ERK1/2 and cPLA(2) by the p55 TNF receptor occurs independently of FAN. Biochem Biophys Res Commun (2000) 0.86
Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Eur Respir J (1997) 0.86
Management of infections during intensive treatment of hematologic malignancies. Ann Hematol (1997) 0.86
[Role of the host in the clinical effect of antibacterial chemotherapy]. Med Klin (1971) 0.86
Pharmacokinetics of new oral cephalosporins, including a new carbacephem. Clin Infect Dis (1993) 0.86
Pharmacokinetics of FCE 22891, a new oral penem. Antimicrob Agents Chemother (1990) 0.86
Inhibitory effect of heparin on neutrophil phagocytosis and burst production using a new whole-blood cytofluorometric method for determination. Eur J Med Res (1997) 0.85
Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis. Infection (1990) 0.85
Quinolone pharmacokinetics and metabolism. J Antimicrob Chemother (1990) 0.85
Studies on the influence of host defence mechanisms on the antimicrobial effect of chemotherapeutic agents. Effect of antibiotics on phagocytosis of mouse-peritoneal-macrophages in vitro. Arztl Forsch (1971) 0.85
[The use of a digital computer in the development of dosage recommendations for antibiotic therapy]. Arzneimittelforschung (1972) 0.85
Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime. Antimicrob Agents Chemother (1993) 0.85
[Pharmacokinetic studies on broad spectrum antibiotic combinations of penicillin and oxacillin in normal volunteers (author's transl)]. Arzneimittelforschung (1979) 0.84
Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother (1993) 0.84
Pharmacokinetics and dose recommendations of carumonam in renal failure. Arzneimittelforschung (1987) 0.84
Antibiotic concentrations in blood and tissue. Intraoperative ischemia as a model for the determination of tissue concentrations using mezlocillin and oxacillin as examples. Arzneimittelforschung (1981) 0.84
Tissue concentrations of mezlocillin in benign hypertrophy of the prostate following intravenous bolus injection versus infusion. J Antimicrob Chemother (1983) 0.84
Modulation of the arterial coronary blood flow by asynchronous activation with ventricular pacing. Pacing Clin Electrophysiol (1995) 0.83
Treatment of childhood meningitis with mezlocillin. Arzneimittelforschung (1979) 0.83
[Pharmacokinetic studies with a combination of mezlocillin-oxacillin]. Arzneimittelforschung (1979) 0.83
Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin. J Antimicrob Chemother (1988) 0.83